Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Vishal Gupta, Ranya Baabbad, Eva Hammerby, Annie Nikolajsen & Asrul Akmal Shafie. (2015) An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. Journal of Medical Economics 18:4, pages 263-272.
Read now
Read now
Frank Nobels, Dirk D’Hooge & Laurent Crenier. (2012) Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results. Current Medical Research and Opinion 28:6, pages 1017-1026.
Read now
Read now
Vasil Valov, James Palmer, Marcin Czech, Alexandra Savova & Guenka Petrova. (2012) Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. Biotechnology & Biotechnological Equipment 26:2, pages 2937-2944.
Read now
Read now
Ryuzo Kawamori & Paul Valensi. (2010) IMPROVE™ observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 5:4, pages 507-516.
Read now
Read now
William J. Valentine, Richard F. Pollock, Juliette Plun-Favreau & Jeremy White. (2010) Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 26:6, pages 1399-1412.
Read now
Read now
Paul Valensi. (2009) Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 2, pages 61-71.
Read now
Read now
Articles from other publishers (26)
Melanie J. Davies, Amra Ciric Alibegovic, Pranav Kelkar, Uffe Christian Braae & Anders Boeck Jensen. (2023)
Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal–bolus insulin in
UK
clinical practice
. Diabetes, Obesity and Metabolism 25:12, pages 3841-3844.
Crossref
Crossref
Viswanathan Mohan, Jagat J Mukherjee, Ashok K Das, Krishna Seshadri & Arundhati Dasgupta. (2021) Initiation and intensification of insulin therapy in type 2 diabetes mellitus: Physician barriers and solutions – An Indian perspective. Endocrine and Metabolic Science 4, pages 100103.
Crossref
Crossref
Ajay Kumar, SurendraKumar Sharma, Arvind Gupta, Arundhati Dasgupta, ArthurJ Asirvatham, PradeepG Talwalkar, AshokKumar Das & Viswanathan Mohan. (2020) Indian reality of managing type 2 diabetes: an expert review of global and national guidelines for optimum insulin use. Journal of Diabetology 11:3, pages 148.
Crossref
Crossref
M. Mnif Feki, A. Tebaibia & H. Baïzri. (2019) Passage d’une insuline biphasique humaine à un analogue d’insuline prémix. Médecine des Maladies Métaboliques 13, pages eS24-eS27.
Crossref
Crossref
Katarzyna Nabrdalik, Hanna Kwiendacz, Tomasz Sawczyn, Andrzej Tomasik, Michał Kukla, Małgorzata Masierek & Janusz Gumprecht. (2018) Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study. International Journal of Endocrinology 2018, pages 1-7.
Crossref
Crossref
Marcin Czech, Elżbieta Rdzanek, Justyna Pawęska, Olga Adamowicz-Sidor, Maciej Niewada & Michał Jakubczyk. (2015) Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
A. Almansari, S. Khader, A. Kharawagh, W. AbdelFattah & T. Badawy. (2014)
Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A
1
chieve study
. International Journal of Clinical Practice 68:7, pages 850-856.
Crossref
Crossref
Elena Viktorovna Surkova. (2013) Ten years of NovoMix 30 in Russian and international clinical practice. Diabetes mellitus 16:4, pages 101-107.
Crossref
Crossref
Alkassem Lezzar, Fatima Ayad, Amine Dahaoui, Abdellah Salah-Mansour & Abdesselam Yahia Berrouiguet. (2013) Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A1chieve study. Diabetes Research and Clinical Practice 101, pages S37-S44.
Crossref
Crossref
Pradana Soewondo, Dharma Lindarto, Sony Wibisono, Olly Renaldi & Tjokorda Gde Dalem-Pemayun. (2013) Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: Results from the Indonesian cohort of the A1chieve study. Diabetes Research and Clinical Practice 100, pages S41-S46.
Crossref
Crossref
Mary Anne Lim-Abrahan, Susan Yu-Gan, Anand B. Jain, Leorino M. Sobrepena & Veronica A. Racho. (2013) Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: Results from the Filipino cohort of the A1chieve study. Diabetes Research and Clinical Practice 100, pages S35-S40.
Crossref
Crossref
Zafar Ahmed Latif, Md. Faruque Pathan, Md. Nazrul Islam Siddiqui, Md. Javed Sobhan, Md. Mahfuzur Rahman & S.M. Ashrafuzzaman. (2013) Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: A sub-analysis of the A1chieve study. Diabetes Research and Clinical Practice 100, pages S30-S34.
Crossref
Crossref
Zanariah Hussein, Mary Anne Lim-Abrahan, Anand B. Jain, Su Yen Goh & Pradana Soewondo. (2013) Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: Results from the ASEAN subgroup of the A1chieve study. Diabetes Research and Clinical Practice 100, pages S24-S29.
Crossref
Crossref
Elena Viktorovna Surkova. (2013) Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30. Diabetes mellitus 16:1, pages 52-56.
Crossref
Crossref
Nabil K. El Naggar, Pradana Soewondo, Mohammad E. Khamseh, Jian-Wen Chen & Jihad Haddad. (2012) Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study. Diabetes Research and Clinical Practice 98:3, pages 408-413.
Crossref
Crossref
Z. Arbouche, A. Lezzar, A. Salah-Mansour & S. Zinai. (2012) Le transfert des insulines humaines vers les analogues de l’insuline entraîne une amélioration de l’HbA1c et une réduction des hypoglycémies chez les patients diabétiques de type 2 : données de la cohorte algérienne de l’étude A1chieve. Médecine des Maladies Métaboliques 6:6, pages 511-518.
Crossref
Crossref
E V Surkova. (2012) Biphasic insulin analog NovoMix 30 is a possible solution to overcome key problems of biphasic human insulin therapy for DM type 2 patients. Problems of Endocrinology 58:4, pages 58-62.
Crossref
Crossref
Matthew Reaney, Katarzyna Cypryk, Nicholas Tentolouris, Michael Jecht, Simon Cleall, Ute Petzinger & Veikko Koivisto. (2012) Resource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: The SWING study. Diabetes Research and Clinical Practice 97:2, pages 231-241.
Crossref
Crossref
Andreas Liebl, Vinay Prusty, Paul Valensi, Ryuzo Kawamori, Jens Sandahl Christiansen, Andrew J. Palmer, Per Balschmidt, Robert Ligthelm & Viswanathan Mohan. (2012) Ten Years of Experience with Biphasic Insulin Aspart 30. Drugs 72:11, pages 1495-1520.
Crossref
Crossref
Jyrki K. Mäkelä, Christine Schmüser, Kari Askonen & Tero Saukkonen. (2012) Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland. Diabetes Research and Clinical Practice 95:1, pages 10-18.
Crossref
Crossref
Naushira Pandya & Esther Nathanson. (2010) Managing Diabetes in Long-Term Care Facilities: Benefits of Switching From Human Insulin to Insulin Analogs. Journal of the American Medical Directors Association 11:3, pages 171-178.
Crossref
Crossref
Kyoung Hee Lee, Se Jin Seo, Jayne Smith-Palmer, James L. Palmer, Jeremy White & William J. Valentine. (2009) Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 12, pages S55-S61.
Crossref
Crossref
S. Shah, M. Benroubi, V. Borzi, J. Gumprecht, R. Kawamori, J. Shaban, M. Shestakova, Y. Wenying & P. Valensi. (2009)
Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix
®
30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
. International Journal of Clinical Practice 63:4, pages 574-582.
Crossref
Crossref
Serdar Guler, Julius A. Vaz & Robert Ligthelm. (2008) Intensification lessons with modern premixes: From clinical trial to clinical practice. Diabetes Research and Clinical Practice 81, pages S23-S30.
Crossref
Crossref
Andreas Liebl. (2008) The PRESENT study: Helping to put clinical trials into clinical practice. Diabetes Research and Clinical Practice 81, pages S1-S2.
Crossref
Crossref
James L. Palmer, Meaghan Gibbs, Huib WKFH Scheijbeler, Robert W. Kotchie, Steffen Nielsen, Jeremy White & William J. Valentine. (2008) Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in Therapy 25:8, pages 752-774.
Crossref
Crossref